Checkpoint Therapeutics, Inc. (CKPT)
Largest Insider Buys in Sector
CKPT Stock Price History Chart
CKPT Stock Performance
About Checkpoint Therapeutics, Inc.
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger …
Insider Activity of Checkpoint Therapeutics, Inc.
Over the last 12 months, insiders at Checkpoint Therapeutics, Inc. have bought $0 and sold $4.28M worth of Checkpoint Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Checkpoint Therapeutics, Inc. have bought $0 and sold $1.08M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 100,000 shares for transaction amount of $127,000 was made by ROSENWALD LINDSAY A MD (director) on 2019‑11‑20.
List of Insider Buy and Sell Transactions, Checkpoint Therapeutics, Inc.
| 2024-12-19 | Sale | CEO, President and Director | 220,230 0.4555% | $3.38 | $744,377 | 0.00% | ||
| 2024-12-18 | Sale | CEO, President and Director | 602,167 1.3953% | $3.87 | $2.33M | 0.00% | ||
| 2024-12-18 | Sale | Chief Financial Officer | 268,432 0.6445% | $4.01 | $1.08M | 0.00% | ||
| 2024-06-26 | Sale | CEO, President and Director | 24,610 0.0674% | $2.05 | $50,451 | +22.22% | ||
| 2024-06-26 | Sale | Chief Financial Officer | 13,038 0.0359% | $2.06 | $26,858 | +22.22% | ||
| 2024-02-28 | Sale | CEO, President and Director | 5,894 0.0247% | $2.06 | $12,142 | +7.07% | ||
| 2024-02-28 | Sale | Chief Financial Officer | 2,035 0.0086% | $2.07 | $4,212 | +7.07% | ||
| 2024-02-01 | Sale | CEO, President and Director | 11,900 0.0552% | $2.01 | $23,919 | +8.67% | ||
| 2024-02-01 | Sale | Chief Financial Officer | 4,115 0.0185% | $1.95 | $8,024 | +8.67% | ||
| 2023-03-02 | Sale | CEO, President and Director | 5,483 <0.0001% | $5.00 | $27,415 | -55.93% | ||
| 2023-03-02 | Sale | Chief Financial Officer | 3,591 <0.0001% | $5.00 | $17,955 | -55.93% | ||
| 2023-02-27 | Sale | CEO, President and Director | 5,548 <0.0001% | $4.65 | $25,798 | -51.41% | ||
| 2023-02-27 | Sale | Chief Financial Officer | 1,914 <0.0001% | $4.66 | $8,919 | -51.41% | ||
| 2023-02-01 | Sale | CEO, President and Director | 10,261 <0.0001% | $4.77 | $48,945 | -50.47% | ||
| 2023-02-01 | Sale | Chief Financial Officer | 3,154 <0.0001% | $4.79 | $15,108 | -50.47% | ||
| 2023-01-10 | Sale | CEO, President and Director | 3,817 <0.0001% | $6.75 | $25,761 | -62.55% | ||
| 2023-01-10 | Sale | Chief Financial Officer | 1,858 <0.0001% | $6.75 | $12,540 | -62.55% | ||
| 2022-06-17 | Sale | CEO, President and Director | 15,000 0.0183% | $1.11 | $16,650 | -44.09% | ||
| 2022-04-13 | Sale | CEO, President and Director | 21,258 0.024% | $1.51 | $32,100 | -35.33% | ||
| 2022-04-05 | Sale | CEO, President and Director | 14,030 0.0164% | $1.77 | $24,833 | -42.20% |
Insider Historical Profitability
| ROSENWALD LINDSAY A MD | director | 237890 0.4942% | $3.64 | 4 | 0 | +32.45% |
Institutional Investor Ownership
| Armistice Capital Llc | $5.57M | 7.36 | 2.72M | +11.95% | +$594,500.00 | 0.02 | |
| The Vanguard Group | $1.88M | 2.49 | 917,894 | +67.41% | +$757,651.42 | <0.0001 | |
| Renaissance Technologies | $556,000.00 | 0.74 | 271,217 | +63.65% | +$216,248.30 | <0.01 | |
| Geode Capital Management | $407,028.00 | 0.54 | 198,501 | +14.18% | +$50,559.39 | <0.0001 | |
| BlackRock | $339,160.00 | 0.45 | 165,444 | -0.64% | -$2,197.60 | <0.0001 |